Glenmark Pharma Q1 Profit Slumps on One-Time Cost; Revenue Flat

Glenmark Pharmaceuticals Ltd. posted a sharp year-on-year drop in its consolidated net profit for the June quarter, hurt by a one-time cost of ₹3.23 billion. The drugmaker’s profit fell to ₹468.71 million, though it jumped over tenfold sequentially as the previous quarter had an exceptional cost of ₹3.73 billion. Excluding the one-time charge, profit stood at ₹3.7 billion.

Consolidated revenue in April–June edged up 0.6% on year to ₹32.64 billion and was 0.3% higher than the previous quarter. Total expenses rose 2.1% to ₹28.72 billion, driven by a 61.5% surge in purchases of stock-in-trade to ₹5.81 billion.
Cost of materials consumed increased 6.8% to ₹7.32 billion, employee costs climbed 7.4% to ₹7.63 billion, and other expenses rose 8.4% to ₹9.06 billion. Finance costs jumped 47.1% to ₹582.26 million.

EBITDA came in at ₹5.81 billion, with a margin of 17.8%.

Revenue from India grew 3.7% to ₹12.40 billion, held back by the discontinuation of tail-end brands and weak diabetes segment sales. North America revenue slipped to ₹7.78 billion from ₹7.81 billion, while Europe revenue fell to ₹6.68 billion from ₹6.96 billion.

The board approved transferring its consumer care business to a wholly owned unit, Glenmark Consumer Care Ltd., to sharpen strategic focus. The business had a turnover of ₹5.15 billion in 2024-25, making up 5.6% of standalone revenue, and a net worth of ₹2.49 billion as of March 31. The transfer is targeted for completion by December 31, 2025.